n-(2-hydroxypropyl)methacrylamide has been researched along with EHS Tumor in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chytil, P; Etrych, T; Fang, J; Islam, R; Mamoru, H; Nakamura, H; Randárová, E; Studenovský, M | 1 |
| Chytil, P; Etrych, T; Fang, J; Haratake, M; Koziolová, E; Maeda, H; Nakamura, H; Tsukigawa, K; Ulbrich, K | 1 |
| Brereton, M; Duncan, R; Maeda, H; Miyamoto, Y; Seymour, LW; Strohalm, J; Ulbrich, K | 1 |
3 other study(ies) available for n-(2-hydroxypropyl)methacrylamide and EHS Tumor
| Article | Year |
|---|---|
Highly effective anti-tumor nanomedicines based on HPMA copolymer conjugates with pirarubicin prepared by controlled RAFT polymerization.
Topics: Acrylamides; Animals; Antineoplastic Agents; Caproates; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Mice; Nanomedicine; Polymerization; Sarcoma, Experimental | 2020 |
Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Topics: Acrylamides; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Proliferation; Doxorubicin; Drug Carriers; Humans; Mice; Mice, Inbred BALB C; Polymers; Sarcoma, Experimental; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier.
Topics: Acrylamides; Animals; Drug Carriers; Iodine Radioisotopes; Macromolecular Substances; Male; Melanoma; Metabolic Clearance Rate; Mice; Molecular Weight; Neoplasms, Experimental; Sarcoma, Experimental; Tumor Cells, Cultured | 1995 |